Skip to main navigation

Investor Relations

Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Coverage

Year

Jun 17, 2022

Addressing Alzheimer Agitation With Phase 3 TRANQUILITY Program of BXCL501

Jun 06, 2022

Vimal Mehta Recognized for Leadership in New Haven Biz Power 25: Healthcare 2022 List

Jun 01, 2022

Current Psychiatry publishes review article by Dr. Leslie Citrome about Igalmi ™ (dexmedetomidine) sublingual film

Apr 19, 2022

BioXcel Launches OnkosXcel to Advance High-Potential Oncology Asset

Apr 19, 2022

On heels of psych drug approval, BioXcel dives head first into oncology R&D with new cash infusion

Apr 07, 2022

FDA Approves Novel Therapy for Schizophrenia and Bipolar

Apr 07, 2022

FDA approves Igalmi for agitation associated with schizophrenia or bipolar I or II disorder

Apr 06, 2022

FDA clears BioXcel's schizophrenia, bipolar treatment Igalmi

Apr 06, 2022

Igalmi Sublingual Film Approved for Agitation With Schizophrenia, Bipolar Disorder

Apr 06, 2022

FDA Approves Dissolving Sublingual Film for Agitation in Schizophrenia, Bipolar I or II

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Investors & Media
Contact Us
Careers

Copyright © 2022 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap